Study on Circulating Tumor Cells and Various Clinical Features and Blood-Related Indexes in Patients with Renal Cancer
- 1 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 2 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 3 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 4 Department of Oncology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 5 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 6 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 7 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 8 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
Abstract
Objective : </b> To investigate the value of CTC clinical features and blood-related test indicators in renal cancer patients by detecting the number of circulating tumor cells (CTC) in patients with renal cancer. <b> Methods : </b> To analyze 59 patients with renal cell carcinoma (RCC) admitted to the Department of Urology, Affiliated Hospital of Chengde Medical College from May 2018 to October 2019. According to the CTC count (5 pcs/3.5 ml), they were divided into CTC positive group and CTC negative group. The age, gender, tumor location, tumor size, hematuria, CEC (circulating endothelial cells), CTC Cluster (aggregate), gene mutation, platelet (PLT), albumin (ALB), hemoglobin (HB), alkaline phosphatase (AKP), lactate dehydrogenase (LDH) were compared between the two groups of patients and the correlation of the number of CTCs. <b> Results : </b> There were significant differences in tumor size, CEC, and gene mutations between the two groups (P < 0.05). The number of CTC in patients was correlated with the levels of HB, PLT and LDH (P < 0.05). <b> C onclusion : </b> The number of CTC in RCC patients is correlated with some clinical features (tumor size, CEC, gene mutation) and some related test indicators (HB, PLT, LDH), and can be combined with the above related indicators to predict the occurrence, metastasis and prognosis of renal cancer.
- Dunnick, N.R. (2016) Renal Cell Carcinoma: Staging and Surveillance. Abdominal Radiology (NY), 41, 1079-1085. https://doi.org/10.1007/s00261-016-0692-0
- Znaor, A., Lortet-Tieulent, J., Laversanne, M., et al. (2015) International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality. European Urology, 67, 519-530. https://doi.org/10.1016/j.eururo.2014.10.002
- Na, J.C., Kim, J.H., Kim, S.Y., et al. (2020) Establishment of Patient-Derived Three-Dimensional Organoid Culture in Renal Cell Carcinoma. Investigative and Clinical Urology, 61, 216-223. https://doi.org/10.4111/icu.2020.61.2.216
- Yang, J., Yang, L., Li, S., et al. (2020) HGF/c-Met Promote Renal Carcinoma Cancer Stem Cells Enrichment through Upregulation of Cir-CCDC66. Technology in Cancer Research & Treatment, 19, 1-8. https://doi.org/10.1177/1533033819901114
- Jiang, W.F. and Zhang, H.L. (2010) Research Progress in the Detection of Circulating Tumor Cells in Peripheral Blood. Journal of Clinical Oncology, 10, 944-947.
- Steeg, P.S. (2006) Tumor Metastasis: Mechanistic Insights and Clinical Challenges. Nature Medicine, 12, 895-904. https://doi.org/10.1038/nm1469
- Maheswaran, S. and Haber, D.A. (2010) Circulating Tumor Cells: A Window into Cancer Biology and Metastasis. Current Opinion in Genetics & Development, 20, 96-99. https://doi.org/10.1016/j.gde.2009.12.002
- Reid, A.H., Attard, G., Danila, D.C., et al. (2010) Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration Resistant Prostate Cancer with the CYP17 Inhibitor Abiraterone Acetate. Journal of Clinical Oncology, 28, 1489-1495. https://doi.org/10.1200/JCO.2009.24.6819
- Sun, S.C. and Sun, Z.W. (2016) Choice of Laparoscopic Inguinal Hernia Surgery: TAPP vs. TEP. Journal of Laparoscopic Surgery, 21, 85-87.
- Ashworth, T.R. (1869) A Case of Cancer in Which Cells Similar to Those in the Tumors Were Seen in the Blood after Death. Australasian Medical Journal, 14, 146-147.
- Benezeder, T., Tiran, V., Treitler, A., et al. (2017) Multigene Methylation Analysis of Enriched Circulating Tumor Cells Associates with Poor Progression-Free Survival in Metastatic Breast Cancer Patients. Oncotarget, 8, 92483-92496. https://doi.org/10.18632/oncotarget.21426
- Politaki, E., et al. (2017) A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. Cellular Physiology and Biochemistry, 44, 594-606. https://doi.org/10.1159/000485115